Core Viewpoint - Intellia Therapeutics, Inc. (NTLA) has seen a 6.1% increase in share price over the past four weeks, closing at $7.69, with analysts suggesting a potential upside of 398.3% based on a mean price target of $38.32 [1] Price Targets and Analyst Consensus - The average of 25 short-term price targets ranges from a low of $7 to a high of $106, with a standard deviation of $24.94, indicating variability in estimates [2] - The lowest estimate suggests a 9% decline from the current price, while the highest indicates a potential upside of 1278.4% [2] - Analysts' price targets should be approached with caution, as their reliability has been questioned [3][7] Earnings Estimates and Market Sentiment - Analysts are optimistic about NTLA's earnings prospects, with a consensus indicating better-than-previously estimated earnings, which historically correlates with stock price movements [4][11] - Over the last 30 days, 10 earnings estimates have been revised upward, resulting in an 8.3% increase in the Zacks Consensus Estimate for the current year [12] - NTLA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13]
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%